Net gamma exposure for ALX Oncology Holdings Inc (ALXO) options was positive at the Nov 4, 2026 close, about $2.35K per 1% move in the stock. It has been positive on 20 of the last 20 trading days. With positive gamma, dealer hedging tends to lean against price moves, which can dampen swings.
Upgrade to unlock Gamma Flip, Gamma Profile, Call Wall, Put Wall, and multiple expiration dates.
Gamma Exposure by Strike
Showing results for ALXO, 2026-11-20(m), calls & puts
Gamma Exposure Stats
Showing results for ALXO, 2026-11-20(m), calls & puts
Net Gamma Exposure by Expiration
Showing results for ALXO, 2026-11-20(m), calls & puts. View all expiries
| Expiration | Net GEX | Call GEX | Put GEX | Call Wall | Put Wall | Gamma Flip |
|---|
ALXO Gamma Exposure FAQ
What is gamma exposure (GEX)?
Gamma exposure estimates how much stock option dealers must buy or sell to stay hedged for each 1% move in the underlying.
Is ALXO gamma exposure positive or negative?
ALX Oncology net gamma exposure was positive on Nov 4, 2026, at $2.35K. It has been positive on 20 of the last 20 trading days.
How has ALXO gamma exposure changed recently?
ALX Oncology net gamma exposure went from $715 on Oct 7, 2026 to $2.35K on Nov 4, 2026. That is its highest reading in 8 weeks. See the ALXO gamma exposure history for a longer view.
What is ALX Oncology Holdings Inc?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials.